Warfarin News and Research

RSS

Warfarin is a drug that prevents blood from clotting. It belongs to the family of drugs called anticoagulants (blood thinners).

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

AstraZeneca announced today that the U.S. Food and Drug Administration has approved the use of NEXIUM I.V. for Injection for children ages greater than 1 month old for the short-term treatment of gastroesophageal reflux disease with erosive esophagitis when oral therapy is not possible or appropriate.

3 May 2011

Many herbal medicines banned under EU directives

According to the new EU rules that came into force over the weekend, hundreds of herbal remedies are now banned. The laws are aimed at protecting consumers from potentially damaging “traditional” medicines.

1 May 2011

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb Company today announced first quarter results that included strong sales and earnings growth, and several key R&D milestones—most notably U.S. regulatory approval for YERVOY. The company also confirmed guidance for the year.

30 Apr 2011

New research: 56% of Canadians with AF do not fear having fatal stroke

New research reveals more than half of Canadians living with atrial fibrillation do not fear having a stroke, despite AF-related strokes being more severe, debilitating and twice as likely to be fatal.

19 Apr 2011

Boehringer Ingelheim's dabigatran etexilate receives positive opinion from EMA committee

Boehringer Ingelheim's novel oral anticoagulant dabigatran etexilate, received a positive opinion from the European Medicines Agency's medicinal committee today.

16 Apr 2011

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

Vitamins, herbs and other dietary supplements are sold as natural alternatives to pharmaceuticals and many people turn to them in an attempt to improve their health. Others seek supplements to lose weight or after hearing that they can help with serious medical conditions.

7 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.

6 Apr 2011

RE-LY trial results suggest Pradaxa capsule reduces risk of stroke in AF patients

Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.

5 Apr 2011

Medical industry veteran set to play key role as Microvisk gears up to launch Smartstrip®

Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.

4 Apr 2011

PGXL to utilize AutoGenomics' automated INFINITI analyzer for personalized medicine applications

PGXL Labs, an internationally recognized pioneer in personalized medicine testing, announced today that it has established a collaborative partnership with AutoGenomics, Inc. wherein they will utilize the automated INFINITI® analyzer for several different personalized medicine applications.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

Merck to return rights for betrixaban to Portola

Portola Pharmaceuticals and Merck, known as MSD outside the United States and Canada, today announced that Merck plans to return to Portola all rights for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation (SPAF). This decision was made following a review of Merck's investigational portfolio.

25 Mar 2011

Dabigatran etexilate is less costly, more effective for stroke treatment in patients with AF

A new economic analysis, published online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor dabigatran etexilate is cost-effective compared to current treatment options, particularly in real-world clinical practice.

25 Mar 2011

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

A new health economic analysis, published today online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor, dabigatran etexilate, is cost-effective compared to current treatment options, particularly in "real-world" clinical practice.

23 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

WARFARIN study to explore impact of genetic testing on individualized dosing

Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN Study was initiated in major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events.

2 Mar 2011

GenMark announces dismissal of microfluidic technology patent lawsuit against Caliper Life Sciences

GenMark Diagnostics Inc. announced today that it has dismissed a lawsuit in the Northern District of California pending since November 2010 that requested declaratory relief that it does not infringe three U.S. patents on microfluidic technology allegedly owned by Caliper Life Sciences, Inc.